{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-012611","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2022-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.011754+00:00","generated_at":"2026-06-24T17:14:26.057217+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"RxSight receives FDA request for additional info on lower-cost LDD; expects no timeline impact","bullets":["FDA requested additional information for approval of lower-cost-to-manufacture Light Delivery Device (LDD).","Commercial sale of the lower-cost LDD not planned until 2023; company believes it can meet the timeline.","Lower-cost LDD has the same functionality as the currently marketed LDD."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-012611","json":"https://secwatch.observer/filing/0000950170-22-012611.json","markdown":"https://secwatch.observer/filing/0000950170-22-012611.md","text":"https://secwatch.observer/filing/0000950170-22-012611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017022012611/0000950170-22-012611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017022012611/rxst-20220711.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T17:14:26.057217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}